TickerTalks
Browse all tickers →
TickerTalks›$NUVL
NUNUVL

Nuvalent, Inc.

$NUVL·$9.1B·Biotechnology·Healthcare
$123.26-0.2%YTD+22.8%1Y+60.5%
Mentions · last 7 days
2026-06-05: 1 posts2026-06-06: 0 posts2026-06-07: 0 posts2026-06-08: 7 posts2026-06-09: 493 posts2026-06-10: 199 posts2026-06-11: 10 posts710+1%
Price updated 17m ago·X counts updated 21h ago
NUNUVL
Nuvalent, Inc.$NUVL
$123.26-0.15%710 posts+1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NUVL, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-06-12

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

GSK announced $10.6B acquisition of Nuvalent — class-action 'fair-price' suits are routine; the deal close is the binary.

Nuvalent is the clinical-stage oncology biotech developing selective kinase inhibitors — and GSK just announced an $11B+ acquisition that brings Nuvalent under Project Nashville, GSK's oncology rebuild. The chart is at fresh 52-week highs as the deal price gets digested. Q1 revenue was $0 (pre-revenue clinical-stage developer) with operating losses driving the -$1.39 EPS. The June 11 GSK announcement of a $10.6B acquisition is the binary — Project Nashville positions Nuvalent's selective kinase inhibitor pipeline as the next leg of GSK's oncology platform. At a $9.08B market cap on the eve of the announcement, the implied $10.6B price reflects a modest premium. Officer insider activity was sized: Darlene Noci $2.46M S-Sale at $122.81 on June 9, James Porter $2.66M S-Sale at $88.53 on June 8 (pre-announcement) — both inside option exercises. The Kahn Swick & Foti and Ademi LLP shareholder investigations are routine 'fair price' class actions that follow every public-target M&A — not material to deal close. The binary is whether GSK's offer closes at $10.6B or gets bumped via competitive process.

What to watch: Deal close timeline (typical 6-9 months for biotech M&A subject to FTC/HSR review), any topping bid from another large pharma (Project Nashville is an open competitive process; AZ/MRK/BMY could counter), and the merger agreement filing for specific deal mechanics (collar, termination fee, conditions). Aug 6 Q2 print is a holding pattern.

On the calendar: 2026-08-06 — Q2 earnings (deal close pending)

acquisition announcedno sentiment

Read the AI verdict + X sentiment for $NUVL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NUVL.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition and clinical binary events are the twin forces bifurcating biotech — ALT and VKTX carry high risk/reward ratios in the obesity race while IBRX's bladder/pancreatic immunotherapy catalysts define the oncology binary calendar. Gene editing (CRSP, BEAM, NTLA) is entering commercial maturation with Casgevy revenue scaling.

See how Biotechnology shapes $NUVL

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $NUVL's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IBBiShares Biotechnology ETF
+0.5%YTD
+33.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-21.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-35.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-42.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-1.39$-1.35-3.0%
Q4 2025Feb 26, 2026$-1.29$-1.48+12.8%
Q3 2025Oct 30, 2025$-1.70$-1.39-22.3%
Q2 2025Aug 7, 2025$-1.31$-1.27-3.1%
Next earningsThu, Aug 6·consensus EPS $-1.44

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.39$-92.4M
Q4 FY25$0———$-1.58$-73.3M
Q3 FY25$0———$-1.70$-70.5M
Q2 FY25$0———$-1.39$-76.6M

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.0M$671K – $37.1M-$5.66-$6.27 – -$5.0615
FY27$188.3M$116.7M – $254.0M-$4.37-$6.25 – -$3.1115
FY28$527.5M$517.7M – $537.3M-$1.30-$4.79 – $3.6117
FY29$940.7M$408.2M – $1.7B$2.82$0.74 – $5.6714
FY30$1.3B$551.6M – $2.3B$5.13$1.36 – $10.358

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.100%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+19.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+25.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 49.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today13.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.155-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Know if $NUVL is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 9Darlene NociChief Development Officer20.0K sh$2.5MSellJun 8Porter James RichardCEO30.0K sh$2.7MSellMay 28Darlene NociChief Development Officer5.5K sh$593KSellMay 28Miller Deborah AnnChief Legal Officer5.5K sh$593KSellMay 4Porter James RichardCEO30.0K sh$3.1MSellMay 1Alexandra BalcomCFO11.4K sh$1.1MSellApr 30Miller Deborah AnnChief Legal Officer5.5K sh$546KSellApr 29Darlene NociChief Development Officer5.5K sh$548KSellApr 9Henry E. PelishChief Scientific Officer2.2K sh$229K
+ 9 other (9 exempts) in window

See when $NUVL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billionmarketbeat.com·1d agoProject Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent dealreuters.com·2d agoNuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVLbusinesswire.com·2d agoShareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholdersgurufocus.com·2d agoShareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholdersprnewswire.com·2d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$IBRX$ALT$RXRX$DARE
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport